In the pipeline from Derek Lowe – Page 8
-
-
-
-
-
OpinionPeace, love and understanding
Chemists and biologists often view the process of drug discovery very differently
-
OpinionThe elements of drug design
Drug discovery requires experimentation, says Derek Lowe. But chemists can be reluctant to stray from the elements they know and love
-
Opinion
The language of the lab
Derek Lowe wonders what the lab lingua franca might be in the years to come
-
Opinion
Rewards of repurposing
Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about
-
-
Opinion
Compounds in the dark
Derek Lowe discusses the compounds you can buy but won't see anywhere in the literature
-
OpinionCommon sense and safety
You have to make space for good sense when thinking about safety, argues Derek Lowe
-
Opinion'Pay for delay'
Derek Lowe considers an increasingly popular business strategy in the drug industry, the much discussed 'pay for delay' deal
-
OpinionThe pitfalls that prevent progress
Derek Lowe highlights the less visible pitfalls on the road to a new drug
-
OpinionThe financial funfair
The financial markets can be a rollercoaster ride, writes Derek Lowe, so should chemists working in industry worry about the company share price?
-
OpinionCategorising chemists
To the unfamiliar, chemists might all look the same. But some common categories are easy to identify, explains Derek Lowe
-
OpinionWho counts as a chemist?
The map of scientific disciplines is growing ever more complex. Derek Lowe surveys the country
-
OpinionThe return of the return of natural products
'Natural products are back!' is a headline Derek Lowe has seen several times before
-
OpinionThe risk vs reward of drug discovery
Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations